Soeder, Yorick and Loss, Martin and Johnson, Christian L. and Hutchinson, James A. and Haarer, Jan and Ahrens, Norbert and Offner, Robert and Deans, Robert J. and Van Bokkelen, Gil and Geissler, Edward K. and Schlitt, Hans J. and Dahlke, Marc H. (2015) First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation. STEM CELLS TRANSLATIONAL MEDICINE, 4 (8). pp. 899-904. ISSN 2157-6564, 2157-6580
Full text not available from this repository. (Request a copy)Abstract
Mesenchymal stem cells and multipotent adult progenitor cells (MAPCs) have been proposed as novel therapeutics for solid organ transplant recipients with the aim of reducing exposure to pharmacological immunosuppression and its side effects. In the present study, we describe the clinical course of the first patient of the phase I, dose-escalation safety and feasibility study, MiSOT-I (Mesenchymal Stem Cells in Solid Organ Transplantation Phase I). After receiving a living-related liver graft, the patient was given one intraportal injection and one intravenous infusion of third-party MAPC in a low-dose pharmacological immunosuppressive background. Cell administration was found to be technically feasible; importantly, we found no evidence of acute toxicity associated with MAPC infusions.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MESENCHYMAL STEM-CELLS; MISOT-I; INFUSION; THERAPY; SAFETY; Multipotent stem cells; Mesenchymal stem cell Liver transplantation; Immunomodulation; Tolerance; Cell therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Jun 2019 13:29 |
| Last Modified: | 25 Jun 2019 13:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/5117 |
Actions (login required)
 |
View Item |
